

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of HBM Holdings Limited (the “**Company**”) dated 12 January 2024, 3 April 2024, 29 April 2025, 2 July 2025, 3 September 2025, 10 September 2025 and 1 January 2026 in relation to the grant of Share Options (each an “**Announcement**” and together, the “**Announcements**”), the interim report of the Company for the six months ended 30 June 2024 (the “**2024 Interim Report**”) and 30 June 2025 (the “**2025 Interim Report**” and together, the “**Interim Reports**”), and the annual report of the Company for the year ended 31 December 2022 (the “**2022 Annual Report**”), 31 December 2023 (the “**2023 Annual Report**”) and 31 December 2024 (the “**2024 Annual Report**” and together, the “**Annual Reports**”). Unless otherwise stated, the terms used in this announcement shall have the same meaning as defined in the Announcements, the Interim Reports and the Annual Reports.

The Company notes that, due to inadvertent clerical and calculation errors, it wishes to clarify the following:

- (i) the number of Shares available for grant under the Share Option Scheme as disclosed in the Announcements dated 12 January 2024, 3 April 2024, 29 April 2025, 2 July 2025, 3 September 2025, 10 September 2025 and 1 January 2026 should be corrected as 37,298,166, 31,472,116, 33,710,216, 30,365,016, 29,620,016, 29,419,016 and 29,217,416, respectively;
- (ii) on page 68 of the 2022 Annual Report, outstanding options as of 31 December 2022 for Employee Participants of the 27 July 2022 option grant shall be corrected as 5,276,000, total outstanding options as of 1 January 2022 shall be corrected as nil, total options granted during the period shall be corrected as 9,318,000, total options cancelled during the period shall be corrected as nil, total options lapsed during the period shall be corrected as 226,000 and total outstanding options as of 31 December 2022 shall be corrected as 9,092,000;
- (iii) on page 68 of the 2023 Annual Report, total Shares available for grant as of the Latest Practicable Date shall be corrected as 31,472,116 (representing approximately 4.09% of the number of the issued share capital of the Company), and on page 70 of the same report, outstanding options as of 1 January 2023 for Employee Participants of the 27 July 2022 option grant shall be corrected as 5,276,000, total outstanding options as of 1 January 2023 shall be corrected as 9,092,000, outstanding options as of 31 December 2023 for Employee Participants of the 27 July 2022 option grant shall be corrected as 2,421,750 and total outstanding options as of 31 December 2023 shall be corrected as 38,193,950;

- (iv) on page 29 of the 2024 Interim Report, total Shares available for grant as of 1 January 2024 shall be corrected as 38,595,166 and total Shares available for grant as of 30 June 2024 shall be corrected as 34,727,416, and on pages 31 and 32 of the same report, outstanding options as of 1 January 2024 for Employee Participants of the 27 July 2022 option grant shall be corrected as 2,421,750, total outstanding options as of 1 January 2024 shall be corrected as 38,193,950, total options granted during the period shall be corrected as 9,605,000, options exercised by Employee Participants of the 3 April 2024 option grant and total options exercised during the period shall be corrected as 386,000, outstanding options as of 30 June 2024 for Dr. Yiping Rong in respect of the 3 April 2024 option grant shall be corrected as 526,000, for Employee Participants of the 27 July 2022 option grant shall be corrected as 1,332,000, for Employee Participants of the 18 April 2023 option grant shall be corrected as 24,467,700, for Employee Participants of the 3 April 2024 option grant shall be corrected as 4,754,000 and total outstanding options as of 30 June 2024 shall be corrected as 41,675,700;
- (v) on page 62 of the 2024 Annual Report, total Shares available for grant as of 1 January 2024 shall be corrected as 38,595,166, total options lapsed/cancelled during the year shall be corrected as 8,692,350, total Shares available for grant as of 31 December 2024 shall be corrected as 37,682,516 and total Shares available for grant as of the Latest Practicable Date shall be corrected as 38,128,916 (representing approximately 4.52% of the number of the issued share capital of the Company), and on page 65 of the same report, outstanding options as of 1 January 2024 for Employee Participants of the 27 July 2022 option grant shall be corrected as 2,421,750, total outstanding options as of 1 January 2024 shall be corrected as 38,193,950, total options lapsed during the year for Employee Participants of the 27 July 2022 option grant shall be corrected as 1,089,750, total options lapsed during the year shall be corrected as 8,692,350 and outstanding options as of 31 December 2024 for Employee Participants of the 18 April 2023 option grant shall be corrected as 22,444,600; and
- (vi) on page 35 of the 2025 Interim Report, total Shares available for grant as of 31 December 2024 shall be corrected as 37,682,516, total options lapsed/cancelled during the period shall be corrected as 1,022,500 and total Shares available for grant as of 30 June 2025 shall be corrected as 30,365,016.

Saved as stated above, all other information in the Chinese and English versions of the Announcements, the Interim Reports and the Annual Reports remains unchanged.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 16 February 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.